Primary and metastatic liver lesions of clinical colorectal cancer differ in chemosensitivity

Y. Maehara, Y. Sakaguchi, Y. Emi, T. Kusumoto, S. Kohnoe, M. Mori, K. Sugimachi

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


The succinate dehydrogenase inhibition (SDI) test was used to examine eight pairs of samples obtained simultaneously from primary colorectal cancers and metastatic liver lesions. The chemosensitivity of the metastatic lesions to six antitumour drugs, carboquone (CQ), adriamycin (ADM), mitomycin C (MMC), aclacinomycin A (ACR), cisplatin (DDP), and 5-fluorouracil (5-FU), differed from that of the primary lesions-the metastatic lesions were less sensitive to all these drugs. There were no correlations of chemosensitivities between the primary and the metastatic lesions (r=-0.4331∼0.4857). Thus, in patients with liver metastasis from a primary colorectal cancer, treatment with these drugs may not be so effective. When selecting antitumour drugs for metastatic liver lesions of colorectal cancer, the chemosensitivity of the primary tumour should first be assessed.

Original languageEnglish
Pages (from-to)87-89
Number of pages3
JournalInternational Journal of Colorectal Disease
Issue number2
Publication statusPublished - May 1 1990

All Science Journal Classification (ASJC) codes

  • Gastroenterology


Dive into the research topics of 'Primary and metastatic liver lesions of clinical colorectal cancer differ in chemosensitivity'. Together they form a unique fingerprint.

Cite this